Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction

Jin Gu Cho1†, Aram Lee1†, Woochul Chang2, Myeong-Sok Lee1 and Jongmin Kim1*

1 Division of Biological Sciences, Sookmyung Women’s University, Seoul, South Korea, 2 Department of Biology Education, College of Education, Pusan National University, Busan, South Korea

Endothelial cells that line the inner walls of blood vessels are in direct contact with blood and display remarkable heterogeneity in their response to exogenous stimuli. These ECs have unique location-dependent properties determined by the corresponding vascular beds and play an important role in regulating the homeostasis of the vascular system. Evidence suggests that vascular endothelial cells exposed to various environments undergo dynamic phenotypic switching, a key biological program in the context of endothelial heterogeneity, but that might result in EC dysfunction and, in turn, cause a variety of human diseases. Emerging studies show the importance of endothelial to mesenchymal transition (EndMT) in endothelial dysfunction during inflammation. EndMT is a complex biological process in which ECs lose their endothelial characteristics, acquire mesenchymal phenotypes, and express mesenchymal cell markers, such as alpha smooth muscle actin and fibroblast-specific protein 1. EndMT is induced by inflammatory responses, leading to pathological states, including tissue fibrosis, pulmonary arterial hypertension, and atherosclerosis, via dysfunction of the vascular system. Although the mechanisms associated with inflammation-induced EndMT have been identified, unraveling the specific role of this phenotypic switching in vascular dysfunction remains a challenge. Here, we review the current understanding on the interactions between inflammatory processes, EndMT, and endothelial dysfunction, with a focus on the mechanisms that regulate essential signaling pathways. Identification of such mechanisms will guide future research and could provide novel therapeutic targets for the treatment of vascular diseases.

Keywords: endothelial dysfunction, inflammatory process, endothelial to mesenchymal transition, endothelial heterogeneity, vascular disease

INTRODUCTION

Endothelial cells (ECs) play a key role in maintaining vascular homeostasis in response to various stimuli. They can regulate vascular tone, permeability, coagulation, and inflammation through the regulation of numerous mediators, such as endothelium-derived relaxing and contracting factor, cell-adhesion molecules, cytokines, and chemokines (1, 2). However, vascular injuries resulting from procedures and conditions, such as angioplasty, stenting, diabetes, hypertension, and immune-mediated damage, can lead to endothelial dysfunction, resulting in disturbance or loss of normal endothelial functions (1, 3–5). Many studies have revealed an association between...
endothelial dysfunction and inflammatory stress in vascular biology. Under conditions of chronic inflammation, sustained activation of ECs by inflammatory stimuli, such as interleukin (IL)-6, tumor necrosis factor-α (TNF-α), IL-1β, and pathogens, cause alterations in normal endothelial function, resulting in impaired endothelial-dependent immune response, which is the hallmark of endothelial dysfunction (6–9). Indeed, endothelial dysfunction due to inflammatory stress contributes to the pathogenesis of many diseases, including fibrosis, atherosclerosis, pulmonary arterial hypertension (PAH), and pathological angiogenesis (10–17). In addition, emerging evidence shows that the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome not only has a role as a critical sensor in immune response, but also has a critical role in endothelial dysfunction and the pathogenesis of vascular diseases, such as atherosclerosis and metabolic syndrome (18–20). Assembly and activation of the NLRP3 inflammasome results in the conversion of the inactive pro-caspase-1 into active caspase-1, with subsequent secretion of mature IL-1β and IL-18 in such diseases (21–25).

Accumulating evidence suggests that endothelial to mesenchymal transition (EndMT) represents a key link in the complex interactions between inflammatory stress and endothelial dysfunction. EndMT is a phenotypic switching process by which ECs lose their characteristics and acquire mesenchymal traits (26, 27). EndMT exhibits features similar to those of epithelial to mesenchymal transition (EMT) and is often considered a specific form of EMT (26, 28). Although both processes use the same signaling pathways and result in cells with a mesenchymal phenotype, studies of the differences between EMT and EndMT are needed due to differences in the origin, fundamental function, and microenvironment of ECs and epithelial cells (29). EndMT was first discovered and has been studied in heart development and emerging studies show that EndMT can occur in postnatal pathologies associated with several diseases, such as fibrosis, cancer, neointima formation, cerebral cavernous malformations, atherosclerosis, and PAH (26, 28–30). Indeed, it has been reported that EndMT contributes to endothelial dysfunction during inflammatory conditions, and that some inflammatory mediators, such as IL-1β, TNF-α, nuclear factor kappa B (NF-κB) transcription factor, and endotoxins, can activate ECs and convert them to mesenchymal-like cells through the EndMT process (6, 7, 31). However, how EndMT contributes to disease progression remains unclear (32), and the specific role of EndMT in inflammatory stimulus-induced endothelial dysfunction has not been fully elucidated due to the dynamic nature of the EndMT process, which consists of multiple steps.

A single layer of ECs lining blood vessels displays heterogeneity in function, morphology, gene expression, and antigen composition depending on location (2) and behaves differently based on its exposure to different microenvironments (33). Therefore, it is also important to understand the molecular basis of inflammation-induced EndMT in the context of endothelial heterogeneity, because this can be critical for developing personalized vascular therapies for patients with vascular bed specific diseases (33).

In this review, we summarize the knowledge currently available regarding the role of EndMT in inflammatory processes and discuss endothelial heterogeneity in the context of inflammation.

**ENDMT MEDIATORS AND SIGNALING PATHWAYS DURING INFLAMMATION**

Endothelial cells play an important role in the maintenance of homeostasis across the entire vascular system (10, 34). ECs actively participate in the regulation of immune responses to various stimuli. To this end, the inflammation-mediated signaling pathway has been extensively studied (6, 17). However, cell signaling associated with inflammation-induced EndMT remains poorly understood. Nevertheless, the molecular mechanisms underlying inflammation-induced EndMT have been gradually identified based on observations of EMT processes that are relatively well studied on inflammatory responses (6). Current evidence suggests that inflammation-induced EndMT, similar to that of EMT, is largely governed by two signaling pathways: the transforming growth factor beta (TGFβ) pathway and the non-TGFβ pathway (35). TGFβ is the most well-known EndMT inducer and upregulates the expression of transcription factors, such as snail, slug, and zinc finger E-box-binding homeobox 1 (ZEB1). These transcription factors then upregulate the expression of mesenchymal markers, such as alpha smooth muscle actin (α-SMA), smooth muscle protein 22 alpha (SM22α), calponin, vimentin, type I collagen, fibronectin, fibroblast-specific protein 1 (FSP-1), N-cadherin, matrix metalloprotein (MMP)-2, and MMP-9 (6, 36, 37).

It has been identified that EndMT related to direct immune responses is triggered in response to pro-inflammatory cytokines, such as TNF-α, IL-1β, and their combinations. Similarly, inflammation-induced EndMT is characterized by the loss of endothelial phenotypes and gain of mesenchymal-like characteristics, and endothelial/mesenchymal markers are tightly controlled by EndMT mediators, such as ZEB1, β-catenin, Akt/NF-κB, snail, slug, Notch1, bone morphogenetic protein (BMP)-4, Sp1, phosphoinositide 3-kinase (PI3K), and enhancer of zeste homolog 2 (EZH2) (Figure 1).

Tumor necrosis factor-α, a pro-inflammatory cytokine, plays an important role in the regulation of various cellular activities (38). In ECs, TNF-α responses are initiated by the binding of one of two receptors, TNF receptor type 1 and TNF receptor type 2, allowing these receptors to activate transcription factors, such as NF-κB, which leads to the induction of transcription of multiple genes such as vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (31, 39–42). TNF-α also induces EndMT through activation of multiple signaling pathways in various ECs types (39, 40, 43, 44). However, future studies will be needed to clarify what type of TNF-α receptor is involved in EndMT. In lymphatic endothelium, TNF-α-induced EndMT occurs through inhibition of vascular endothelial (VE)-cadherin expression while increasing the expression of β-catenin, N-cadherin, and ZEB1, key molecules involved in the EndMT processes (44). A previous study (40) showed that TNF-α drives
EndMT through Akt/NF-κB activity in both embryonic and adult-valve endothelium, finding that EndMT-related protein expression involving α-SMA and snail was significantly upregulated, whereas VE-cadherin was significantly downregulated in response to TNF-α in porcine aortic valve ECs (PAVECs), but not porcine aortic ECs (40); suggesting the importance of determining the molecular mechanism of EndMT in the context of endothelial heterogeneity during inflammation. The same group also demonstrated heterogeneous susceptibility to EndMT in PAVECs in response to TNF-α. Under TNF-α stimulation, non-transforming
cells that maintain endothelial-cell marker expression and transforming cells that acquire mesenchymal-marker expression were isolated using membrane-based three-dimensional culture systems. Transforming cells decreased endothelial marker expression, such as VE-cadherin and endothelial nitric oxide synthase and acquired mesenchymal markers, such as α-SMA, Notch1, MMP-9, BMP-4, and TGFβ in PAVECs (Figure 2) (39).

Interleukin-1β is a proinflammatory cytokine (45) involved in endothelial dysfunction (46) and a key inducer of EndMT. IL-1β-induced phenotypic changes in ECs were first demonstrated in IL-1β-treated human dermal microvascular ECs undergoing morphological changes and cytoskeletal reorganization, in addition to decreased expression of typical endothelial markers, such as von Willebrand Factor (vWF) and CD31 (47). In addition, long-term exposure of human dermal microvascular ECs to IL-1β induces the expression of mesenchymal markers such as α-SMA, type I collagen, and calponin and inhibits the expression of vWF (48). Maleszewksa et al. (49) reported that the molecular mechanism underlying IL-1β-induced EndMT involves increased expression of SM22α, which is encoded by TAGLN. Their results demonstrated the epigenetic regulation of TAGLN via EZH2, which acts as a key negative regulator in IL-1β-induced EndMT (49). Moreover, in corneal ECs, IL-1β induced an EndMT phenotype by increasing fibroblast growth factor (FGF) expression through the PI3K-signaling pathway (50, 51) in accordance with changes in the actin cytoskeleton and cellular morphology (Figure 2). The most recent study has shown that the NLRP3 inflammasome, closely associated with mature IL-1β secretion, is involved in mechanical stretch-induced EndMT in lung fibrosis and NLRP3 inactivation could inhibit EndMT, suggesting novel therapeutic options against mechanical ventilation-induced pulmonary fibrosis (52).

Several studies reported that a combination of cytokines, including TNF-α, IL-1β, and TGFβ, is more powerful than a single cytokine at inducing EndMT. The combination of TGFβ1, IL-1β, and TNF-α induces EndMT via the Sp1 transcription factor, which is a key transcriptional regulator of EndMT-related genes in human intestinal microvascular endothelial cells (31). TGFβ2 and IL-1β synergistically induce EndMT through increased expression of mesenchymal markers while decreasing the

![Figure 2](https://www.frontiersin.org)
expression of endothelial markers in human esophageal microvascular endothelial cells and human umbilical vein ECs (HUVECs) (53, 54). The combination of TNF-α, IL-1β, and TGFβ1 also induces EndMT in pulmonary artery ECs, with EndMT cells exhibiting morphological changes, as well as changes in endothelial and mesenchymal markers (7).

Emerging evidence has shown that endothelial dysfunction induced by metabolic disorders such as obesity, hyperglycemia, and dyslipidemia is critically associated with induction of EndMT. Several studies have demonstrated that high glucose induces EndMT, which leads to increased expression of mesenchymal markers, such as α-SMA, FSP-1, type I collagen, fibronectin, vimentin, and MMP-2 along with decreased expression of endothelial markers CD31 and VE-cadherin in various EC types (55–57). It was shown that high-glucose-induced EndMT occurs through positive regulators, such as Smad2/3, Snail, Rho-associated kinase 1 (ROCK1), serum response factor (SRF), nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and ERK in glomerular ECs (57–60). In human aortic ECs (HAECs) and HUVECs, high glucose also induces EndMT through positive regulators, such as angiotensin II, poly (ADP-ribose) polymerase 1 (PARP-1), endothelin 1 (ET-1), Smad, Akt, p38, and ERK, contributing to diabetic cardiomyopathy (55, 56, 61–63). It has also been shown that oxidized low-density lipoprotein (ox-LDL) accelerates radiation-induced EndMT in HAECs and contributes to radiation-induced atherosclerosis (64), whereas high-density lipoprotein (HDL) inhibits TGFβ1-induced EndMT in HAECs suggesting anti-fibrotic effects of HDL (Figure 2) (65).

Although much attention has recently been directed to EndMT because of its importance in many diseases, most studies have been limited to the identification of endothelial and mesenchymal markers in response to inducers of EndMT. Therefore, elucidation of the potential molecular mechanisms regulating pathological EndMT induced by inflammatory stimuli will be important in the future. Table 1 shows a summary of the main studies exploring EndMT under specific inflammatory stimuli and metabolic dysfunction, including EndMT mediators, endothelial and mesenchymal markers, and EC types.

### EC HETEROGENEITY DURING INFLAMMATION

Endothelial cells line the inner wall of blood vessels and exhibit diverse subtypes (2, 8, 33). Different ECs have different structural and functional characteristics based on their exposure to distinct microenvironments (2, 8, 9, 33, 66). They are activated in response to inflammatory stimuli, with this activation resulting in the expression of adhesion molecules necessary for leukocyte binding (33).

| Stimuli | Endothelial markers | Mesenchymal markers | Endothelial cell types | Positive regulator of EndMT | Reference |
|---------|---------------------|---------------------|------------------------|-----------------------------|-----------|
| TNF-α   | VE-cadherin         | N-cadherin          | LEC                    | ZEB1 and β-catenin          | (44)      |
| TNF-α   | VE-cadherin, CD31, eNOS | α-SMA and MMP-9 | PAVEC                  | Akt/PI3K, αB, Slit, TGFβ3, and eQEE | (59, 40) |
| IL-1β   | vWF                | α-SMA, collagen I, and calponin | HDMEC                  | Non determined              | (47, 48) |
| IL-1β   | Non determined     | SM22α               | HIMEC                  | pSmad2 and TGFβ2           | (49)      |
| TGFβ1 and IL-1β | VE-cadherin, CD31, and vWF | α-SMA, FSP-1, vimentin, N-cadherin, and fibronectin | HEMEC                  | Snail         | (53)      |
| TGFβ2 and IL-1β | CD31, vWF, and VE-cadherin | SM22α, FSP-1, collagen I A2, vimentin, and α-SMA | HEMEC                  | Not determined | (54)      |
| TNF-α, IL-1β and TGFβ1 | eNOS and vWF | Calponin, α-SMA, and collagen I | PAECs                  | Non determined              | (7)       |
| High glucose | CD31 and VE-cadherin | α-SMA, α-SMA, FSP-1, and fibronectin | GEnC                   | TGFβ1, pSmad3/2, Snail, ROCK1, NOD1, MEK/ERK, SP, and Snail | (57–60) |
| High glucose | CD31 and VE-cadherin | α-SMA, FSP-1, collagen I, collagen III, and MMP-2/9 | HAEC                  | Angiotensin II, Snail, and PARP-1 | (55, 61) |
| High glucose | VE-cadherin and CD31 | α-SMA, collagen I, FSP-1, vimentin, and MMP-2/9 | HUVEC                  | TGFβ1, ERK, pSmad2/3, and MAPK (p38 and ERK) | (56, 63) |
| High glucose | VE-cadherin | FSP-1 and collagen I | HUVEC and HAEC | ET-1, TGFβ1, pSmad3, pAKT, and Snail | (62) |
| ox-LDL + Radiation | VE-cadherin and CD31 | α-SMA, FSP-1, and vimentin | HAEC                  | Non determined              | (64)      |

TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; TGFβ, transforming growth factor-β; VE-cadherin, vascular endothelial cadherin; eNOS, endothelial nitric oxide synthase; vWF, von Willebrand Factor; α-SMA, α-smooth muscle actin; SM22α, smooth muscle protein 22α; FSP-1, fibroblast-specific protein 1; LEC, lymphatic endothelial cell; PAVEC, porcine aortic valve endothelial cell; eQEE, embryonic quail endocardial explant; HDMEC, human epithelial dermal microvascular endothelial cell; HUVEC, human umbilical vein endothelial cell; CEC, corneal endothelial cell; HIMEC, human intestinal microvascular endothelial cell; HEMEC, human esophageal microvascular endothelial cell; PAEC, pulmonary artery endothelial cell; ZEB1, zinc finger E-box binding homeobox 1; NF-κB, nuclear factor kappa B; BMP-4, bone morphogenetic protein 4; EZH2, enhancer of zeste homolog 2; P2X2, fibroblast growth factor 2; PI3K, phosphatidylinositol 3-kinase; GEnC, glomerular endothelial cell; ROCK1, Rho-associated kinase 1; HAEC, human aortic endothelial cell; GLP-1, glucagon-like peptide-1; PARP-1, Poly (ADP-ribose) polymerase 1; SRF, Serum response factor; ET-1, endothelin-1; ox-LDL, oxidized low-density lipoprotein; NOD2, Nucleotide-binding oligomerization domain-containing protein 2.
Many studies showed that each EC subtype responds differently to different inflammatory stimuli in vitro (33). Viemann et al. (67) suggested that genes differentially regulated upon TNF-α stimulation between human microvascular ECs and HUVECs exhibit functional differences, and that genes whose expression was altered only in the human microvascular ECs group were associated with signaling and transcription factors, apoptosis, cell proliferation, immune response, and cell structure. However, genes showing altered expression only in HUVECs were associated with chemokines, cytokines, cell-surface molecules, and signaling and transcription factors (67). VCAM-1 expression was only increased in response to TNF-α in HUVECs and glomerular ECs, but not in dermal microvascular ECs (68). In addition, Scott et al. (69) reported changes in heterogeneous gene expression in response to TNF-α, lipopolysaccharide (LPS), and IL-1β in HUVECs, human pulmonary microvascular ECs, HAECs, carotid artery ECs, coronary artery ECs, subclavian artery ECs, and brachiocephalic artery ECs. TNF-α, and IL-1β-stimulated organ-specific endothelial heterogeneity has also been reported (70).

These findings suggest that each EC subtype might respond differently to different inflammatory stimuli in the context of EndMT. Indeed, Pinto et al. (71) compared responses to TGFβ1 or TGFβ2 between human coronary artery ECs and microvascular pulmonary artery ECs, finding that in human coronary artery ECs, both TGFβ1 and TGFβ2 upregulated the expression of the mesenchymal markers α-SMA and SM22α, but only TGFβ1 had an effect on α-SMA expression in human pulmonary microvascular ECs. In addition, TNF-α increased the expression of the mesenchymal markers in PAVECs, although this response was not observed in porcine aortic ECs (40).

Importantly, other inflammation-associated endothelial activators, such as shear stress or protein kinase C (PKC), have also been studied in this context (33). Methe et al. (72) showed that venous and coronary artery specific flows differentially regulate the expression of endothelial adhesion molecules as well as KLF2/KLF4 transcription factors in human saphenous vein ECs and human coronary artery ECs. Two ECs have also been reported to show heterogeneity in adhesion molecule expression in response to PKC. Here, PKC activation induces E-selectin and VCAM-1 expression in HUVECs, but not in human dermal microvascular ECs (73).

Differences in the behavior of various EC subtypes in response to inflammatory stimuli have also been reported in vivo (33). Tamara et al. (74) showed that induction of adhesion molecule expression in response to IL-1β stimulation is both tissue- and cell-type specific. However, no changes were observed in VCAM-1 expression in brain and liver microvascular ECs in response to LPS stimulation (75, 76). Furthermore, van Meurs et al. (77) showed that E-selectin and VCAM expression in human glomerular ECs differs from that in other ECs. In CD31-deficient mice, apoptosis of peritubular-capillary ECs occurs upon LPS administration, although other microvascular ECs were unaffected (78). Given the extent of endothelial heterogeneity found both in vitro and in vivo, studying the molecular mechanisms and functions associated with the EndMT process in inflammation in the context of endothelial heterogeneity will eventually enable us to better understand vascular diseases and develop more sophisticated and effective therapeutic drugs.

**TARGETING ENDMT FOR THERAPEUTIC AND CLINICAL APPLICATIONS IN VASCULAR DISEASES**

Endothelial to mesenchymal transition is recognized to not only occur during development but also is now clear that EndMT underlies pathological processes associated with multiple diseases (6, 26, 79, 80). EndMT is also controlled by a variety of stimuli, including inflammation, growth factors, and hypoxia (81–83). Particularly, inflammation-induced EndMT aggravates inflammation and destroys vascular homeostasis, leading to pathogenesis of several diseases, such as cardiac fibrosis, PAH, and atherosclerosis (31, 84, 85). Given the involvement of EndMT in multiple inflammatory diseases, preventing EndMT may represent a useful approach to treat inflammatory diseases.

Several factors have been identified as the negative regulators of EndMT signaling pathways (86–88). Vascular endothelial growth factor-A reverses TGFβ2-induced EndMT (89), and HDL and the extracellular-matrix protein fibulin 1 and kallistatin also exert inhibitory effects on TGFβ-induced EndMT (65, 90, 91). Furthermore, the most common aldosterone receptor antagonist, spironolactone has a protective role against TGFβ-induced EndMT in HUVECs (92) and, rapamycin suppresses mechanistic target of mTOR signaling, leading to the inhibition of EndMT (93). Although emerging studies report multiple EndMT mediators that play critical roles in EndMT induction, the targeting of EndMT mediators requires careful evaluation due to the modulation of EndMT exhibiting differential effects in different ECs based on endothelial heterogeneity. For example, IL-1β upregulates FGF2 expression through PI3K activation, which leads to EndMT of corneal ECs (51). Lee et al. (50) suggested that blocking the IL-1β and FGF2 pathways would prevent inflammation-induced EndMT in corneal ECs; however, FGF2 exerts an inhibitory effect on TGFβ-mediated EndMT via miR-20a in HUVECs (81, 94). Moreover, another study showed that FGF receptor-1 is a key inhibitor of TGFβ-driven EndMT in HUVECs (95), and the endogenous anti-fibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline restores FGF receptor levels and upregulates levels of the let-7, resulting in the inhibition of EndMT in human dermal microvascular ECs (96). Therefore, further studies are needed to completely elucidate the mechanisms associated with FGF2, as well as many mediators involved in EndMT (81).

In the context of diseases, studies on the inhibitory effect of EndMT have mainly focused on fibrosis. The common feature of many fibro-proliferative diseases is inflammation (97). Fibrosis results from chronic inflammation, possibly owing to infection, autoimmune reactions, or allergic reactions, which results in the release of inflammatory mediators, abnormal cell proliferation, and deposition of extracellular-matrix components (81, 82, 84, 97). BMP7 has been shown to exhibit anti-EndMT effects and reduce cardiac fibrosis; however, most other BMPs are positive regulators of EndMT (81, 85, 98, 99). Hepatocyte growth factor
reduces cardiac fibrosis by suppressing TGFβ1-mediated EndMT (100). Cinacalcet, a calcimimetic agent, reduces serum levels of parathyroid hormone and suppresses EndMT, leading to attenuation of cardiac fibrosis (101). Similarly, losartan and irbesartan, two angiotensin II-receptor type 1 blockers, ameliorate cardiac fibrosis by inhibiting EndMT (61, 102). Scutellarin and relaxin are also EndMT inhibitors and prevent cardiac fibrosis by regulating Notch1 and Jagged-1 (86, 103). Furthermore, inhibition of CD45 protein tyrosine phosphatase leads to reduced EndMT in TGFβ1-treated mitral valve ECs (104). The anti-fibrotic effects of linagliptin, which blocks EndMT, have also been reported in vitro and in diabetic kidneys (105). Similarly, macitentan inhibits endothelin-1 or TGFβ1-induced EndMT in systemic sclerosis (106).

Cytokine-induced inflammation is widely considered a major cause of PAH development (107). Moreover, remodeling of the pulmonary artery under inflammatory conditions is a major feature of PAH (12–15). Recent evidence suggests that inflammation-induced EndMT is a key contributor to pathological pulmonary vascular remodeling associated with transition of ECs to α-SMA-expressing mesenchymal-like cells in obstructive vascular lesions of PAH (7, 29). Clinical data also indicate that the serum levels of IL-1, -6, -8, -10, and TNFα are elevated in PAH patients (107). In this context, salvianolic acid A, a polyphenol compound, inhibits EndMT in PAH, thereby attenuating inflammation associated with monocrotaline-induced PAH (108). Another study showed that the delivery of BMP receptor-2 resulted in less right-ventricle hypertrophy, pulmonary vascular resistance, and improved cardiac function through attenuation of EndMT (109). Kang et al. (87) suggested that ponatinib, a multi-target tyrosine-kinase inhibitor, delays TGFβ1-mediated EndMT and has therapeutic potential for use in PAH therapy, where it could act by regulating Wnt signaling.

Atherosclerosis is a vascular disease mediated by a typical inflammatory response. Inflammatory stimuli continuously lead to calcified plaque formation (110). Atherosclerosis lesions mostly comprise EndMT-derived fibroblast-like cells, which are regulated by various EndMT mediators, such as snail, slug, and β-catenin (84, 111, 112). Other pathways might also lead to atherosclerosis by inducing EndMT via TGFβ, oxidative stress, hypoxia, Wnt/β-catenin signaling, and BMP signaling (81, 84, 113). These data suggest that EndMT is a major source of neointimal hyperplasia and plays a role in the progression of arteriosclerosis through inflammation. In particular, excessive BMP activity promotes the calcification of atherosclerotic lesions through EndMT and serine-protease inhibitors also reduce EndMT and vascular calcification (88, 114). Consistent with this report, vascular calcification was found to be reduced in response to a BMP inhibitor in matrix-gla-protein-deficient mice (115).

It has been shown that metabolic syndrome, which is associated with metabolic dysfunction such as obesity, hyperglycemia, insulin resistance, and dyslipidemia has a central role in the development of atherosclerotic lesions. The potential for use in PAH therapy, where it could act by regulating Wnt signaling.

| Model of Study | Negative regulator of EndMT | Clinical relevance | Reference |
|----------------|-----------------------------|--------------------|-----------|
| Isoproterenol-induced myocardial fibrosis rat model | Relaxin | Cardiac fibrosis | (86) |
| Bleomycin-induced PAH model | Ponatinib (multi-targeted tyrosine-kinase inhibitor) | Pulmonary arterial hypertension (PAH) | (87) |
| TGFβ1-induced EndMT | Losartan (angiotensin II receptor type 1 blocker) | Non-determined | (65) |
| Mouse models of pressure overload and chronic allograft rejection | BMP-7 | Cardiac fibrosis | (85) |
| Heterotopic heart transplantation model | BMP-7 | Endocardial fibroelastosis | (89) |
| Pressure-overload mouse model | HGF | Cardiac fibrosis | (100) |
| Rat model of uremia and secondary hyperparathyroidism | Cinacalcet (calcimimetic agent) | Cardiac fibrosis | (101) |
| TGFβ1-induced EndMT | Scutellarin | Non-determined | (102) |
| Isoproterenol-induced myocardial fibrosis rat model | CGG-1423 (SRF inhibitor) | Cardiac fibrosis | (85) |
| Obv A inferior myoccardial infarction model | Macitentan (ET-1 receptor antagonist) | Non-determined | (103) |
| STZ-induced diabetic mice | Salvinolic acid A | Diabetic kidney fibrosis | (105) |
| TGFβ1 and ET-1-induced EndMT | Delivery of BMPR2 | Systemic sclerosis | (106) |
| MCT-induced PAH model | Low-dose irisin | Pulmonary arterial hypertension | (108) |
| Hypoxia, MCT-induced PAH model | Delivery of BMPR2 | Pulmonary arterial hypertension | (109) |
| STZ-induced diabetic rats | Lovastatin | Diabetic nephropathy | (58) |
| db/db diabetic rats | Fasudil (ROCK1 inhibitor) | Diabetic nephropathy | (59) |
| STZ-induced SHR diabetic rats | Angiotensin II receptor type 1 blocker | Diabetic cardiomyopathy | (61) |
| STZ-induced diabetic mice | GLP-1 analog | Diabetic cardiomyopathy | (55) |
| STZ-induced diabetic rats | CCG-1423 (SRF inhibitor) | Diabetic nephropathy | (57) |
| STZ-induced diabetic ET-1; Tie2-Cre(+) mice | ET-1 silencing | Diabetic cardiomyopathy | (62) |
| STZ-induced diabetic mice | Low-dose irisin | Diabetic cardiomyopathy | (63) |
| TGFβ1-induced EndMT | HDL | Non-determined | (65) |

**TABLE 2** | Summary of the key studies exploring endothelial to mesenchymal transition (EndMT) as a therapeutic target in various diseases.

**TFNα**, tumor necrosis factor-α; **IL-1β**, interleukin-1β; **TGFβ1**, transforming growth factor-β; **VE-cadherin**, vascular endothelial cadherin; **eNOS**, endothelial nitric oxide synthase; **WVF**, von Willebrand factor; **α-SMA**, α-smooth muscle actin; **SM22α**, smooth muscle protein 22α; **FSP-1**, fibroblast-specific protein 1; **LEO**, lymphatic endothelial cell; **PAEC**, porcine aortic valve endothelial cell; **eQEG**, embryonic quail endocardial explant; **HMEC**, human epithelial dermal microvascular endothelial cell; **HUVEC**, human umbilical vein endothelial cell; **CEC**, cecal endothelial cell; **HIMEC**, human intestinal microvascular endothelial cell; **MEMC**, human esophageal microvascular endothelial cell; **PAEC**, porcine pulmonary artery endothelial cell; **ZEB1**, zinc finger E-box binding homeobox 1; **NFκB**, nuclear factor kappa B; **BMP-4**, bone morphogenetic protein 4; **EZH2**, enhancer of zeste homolog 2; **FGF2**, fibroblast growth factor 2; **PDK3**, phosphatidylidyinositol 3-kinase. **STZ**, streptozotocin; **SHR**, spontaneously hypertensive rats; **HDL**, High-Density Lipoproteins; **HGF**, hepatocyte growth factor; **MCT**, monocrotaline.
pathogenesis of cardiovascular disease, diabetes mellitus type 2, and tissue remodeling (116). Abnormalities associated with chronic inflammation are key risk factors of metabolic dysfunction, leading to the endothelial dysfunction that is critically involved in the development of such diseases (64, 116–119). In the context of metabolic syndrome, studies on EndMT induced by metabolic dysfunction have mainly focused on diabetic nephropathy and cardiomyopathy. Several studies have shown that EndMT contributes to diabetic nephropathy, while inhibition of EndMT by lovastatin, fasudil, and CCG-1423 could ameliorate diabetic nephropathy in streptozotocin (STZ)-induced diabetic animal models (57–59). In addition, inhibition of EndMT by Irbesartan, glucagon-like peptide-1 analog, ET-1 inhibition and low-dose irisin could prevent diabetic cardiomyopathy in diabetic animal models (55, 61–63).

Taken together, the currently available data indicate that EndMT plays a key role in various fibrosis-related and cardiovascular diseases (Figure 1; Table 2). Considering the large number of studies that suggest targeting EndMT as a novel therapeutic approach for many diseases, clarifying the underlying signaling mechanisms associated with EndMT and establishing strategies to regulate EndMT are urgently needed.

CONCLUSION

Endothelial to mesenchymal transition plays an important role not only during the development process but also in adults under physiological and pathological conditions. A central role for EndMT emerges from the complex network of interactions that underlie inflammation-induced endothelial dysfunction. There is accumulating evidence indicating that EndMT is a key feature in inflammation-related endothelial dysfunction. It is through this phenotypic switch that EndMT causes diverse vascular diseases, such as atherosclerosis, PAH, and fibrosis. Therefore, the modulation of EndMT might yield new therapeutic strategies for the treatment of diverse diseases. Although our current understanding of the molecular mechanisms underlying EndMT in the context of inflammation is advancing, further studies are needed in the future to completely understand the molecular mechanism associated with EndMT in inflammation-related diseases. Given that heterogeneity is apparent in ECs of different organs in response to different inflammatory stimuli, it will also be important to determine the molecular mechanisms associated with EndMT in the context of endothelial heterogeneity during inflammation in future studies. In conclusion, the study of EndMT will provide valuable insights into the molecular mechanisms leading to various human diseases and will help develop more sophisticated and effective therapeutic drugs for patients suffering from these diseases.

AUTHOR CONTRIBUTIONS

JK, JC, and AL wrote the manuscript. JK, WC, and MS-L were critically involved in the design of the work and the discussion of the content. All the authors approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank Dr. Danielle L. McLean for her critical review of the manuscript and thoughtful discussions.

FUNDING

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the minister of Education, Science and Technology (NRF-2016R1A5A1011974 and NRF-2016R1C1B2006591 to JK).

REFERENCES

1. Sena CM, Pereira AM, Seica R. Endothelial dysfunction – a major mediator of diabetic vascular disease. Biochim Biophys Acta (2013) 1832(12):2216–31. doi:10.1016/j.bbadis.2013.08.006
2. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med (2012) 2(1):a006429. doi:10.1101/cshperspect.a006429
3. Gimbrone MA Jr, Garcia-Cardenas G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res (2016) 118(4):620–36. doi:10.1161/CIRCRESAHA.115.306301
4. Vanhoucke PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease – a 50th anniversary update. Acta Physiol (Oxf) (2017) 219(1):22–96. doi:10.1111/apha.12646
5. Juni RP, Duckers HJ, Vanhoucke PM, Virmani R, Moens AL. Oxidative stress and pathological changes after coronary artery interventions. J Am Coll Cardiol (2013) 61(14):1471–81. doi:10.1016/j.jacc.2012.11.068
6. Perez L, Munoz-Durango N, Riedel CA, Echeverria C, Kalerjis AM, Cabello-Verrugio C, et al. Endothelial-to-mesenchymal transition: cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev (2017) 33:41–54. doi:10.1016/j.cytogfr.2016.09.002
7. Good RB, Gilbane AJ, Trinder SL, Denton CP, Coghlan G, Abraham DJ, et al. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am J Pathol (2015) 185(7):1850–8. doi:10.1016/j.ajpath.2015.03.019
8. Kim JD, Lee HW, Jin SW. Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cells. Arterioscler Thromb Vasc Biol (2014) 34(9):1838–45. doi:10.1161/ATVBAHA.114.303219
9. Aird WC. Phenotypic heterogeneity of the endothelium: II. representative vascular beds. Circ Res (2007) 100(2):174–90. doi:10.1161/01.RES.0000255690.03436.ae
10. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci (2013) 9(10):1057–69. doi:10.7150/ijbs.7502
11. Lee A, Papangeli I, Park Y, Jeong HN, Choi J, Kang H, et al. A PPARgamma-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. Sci Rep (2017) 7(1):2528. doi:10.1038/s41598-017-02852-4
12. Lee A, McLean D, Choi J, Kang H, Chang W, Kim J. Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep (2014) 47(6):311–7. doi:10.5483/BMBRep.2014.47.6.085
13. Kim JD, Lee A, Choi J, Park Y, Kang H, Chang W, et al. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. Exp Mol Med (2015) 47:e175. doi:10.1038/emm.2015.45
14. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, et al. An endothelial apelin-FGF link mediated by mir-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med (2013) 19(1):74–82. doi:10.1038/nm.3040
15. Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D, et al. Restoration of impaired endothelial myocyte enhancer factor 2 function
rescues pulmonary arterial hypertension. *Circulation* (2015) 131(2):190–9. doi:10.1161/CIRCULATIONAHA.114.013339

16. Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: What is the link? *Kidney Int* (2003) 63:845–9. doi:10.1046/j.1523-1755.63.s8.12.x

17. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. *Basic Res Cardiol* (2008) 103(5):398–406. doi:10.1007/s00395-008-0733-0

18. Chen Y, Pitzer AL, Li X, Li PL, Wang L, Zhang Y. Instigation of endothelial Nlrp3 inflammation by adipokine visfatin promotes inter-endothelial junction disruption: role of HMGB1. *J Cell Mol Med* (2015) 19(12):2715–27. doi:10.1111/jcmm.12667

19. Vandana et al. Molecular cloning of the interleukin-1 beta converting enzyme. *Science* (1992) 256(5053):97–100. doi:10.1126/science.1373520

20. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. *Nat Immunol* (2012) 13(4):325–32. doi:10.1038/ni.2231

21. Chen J, Martin M, Li Z, Shyy JY. Endothelial dysfunction: the role of sterol regulatory element-binding protein-induced NOD-like receptor family pyrin domain-containing protein 3 inflammation in atherosclerosis. *Curr Opin Lipidol* (2014) 25(3):339–49. doi:10.1097/MOL.0b013e3283000000

22. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, et al. Molecular cloning of the interleukin-1 beta converting enzyme. *Science* (1992) 256(5053):97–100. doi:10.1126/science.1373520

23. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Sanchez-Duffhues G, Orlova V, Ten Dijke P. In brief: endothelial-to-mesenchymal transition of human atherosclerosis. *Nat Med* (2011) 17(2):179–88. doi:10.1038/nm.2279

24. Varghese GP, Folkersen L, Strawbridge RJ, Halvorsen B, Yndestad A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Am J Pathol* (2011) 179(5):2660–73. doi:10.1016/j.ajpath.2011.08.003

25. He Y, Zeng MY, Yang DH, Metro B, Nunez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. *Nat Immunol* (2012) 13(4):325–32. doi:10.1038/nature11699

26. Chen PY, Simons M. When endothelial cells go rogue. *EMBO Mol Med* (2016) 8(1):1–2. doi:10.15252/emmm.201505943

27. Ghosh AK, Quaggin SE, Vaughan DE. Molecular basis of organ fibrosis: potential therapeutic approaches. *Exp Biol Med (Maywood)* (2013) 238(4):461–81. doi:10.1177/1535370213489441

28. Potenta S, Zeiberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. *Br J Cancer* (2008) 99(9):1375–9. doi:10.1038/sj.bjc.6604662

29. Arciniegas E, Fried MG, Douglas IS, Stammark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* (2007) 293(1):L1–8. doi:10.1152/ajplung.00378.2006

30. Sanchez-Duffhues G, Orlova V, Ten Dijke P. In brief: endothelial-to-mesenchymal transition. *J Pathol* (2016) 238(3):378–80. doi:10.1002/ajp.24856

31. Rieder F, Kessler SP, West GA, Bhiloca S, de la Motte C, Sadler TM, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. *Am J Pathol* (2011) 179(5):2660–73. doi:10.1038/ajpath.2011.07.042

32. Welch-Readon KM, Wu N, Hughes CC. A role for partial endothelial-to-mesenchymal transitions in angiogenesis? *Arterioscler Thromb Vasc Biol* (2015) 35(2):303–8. doi:10.1161/ATVBAHA.114.303220

33. Dauphinee SM, Karsan A. Endothelial Dysfunction and Inflammation. *Basel: Birkhäuser* (2010). xii,234 p.

34. Yu QC, Song W, Wang D, Zeng YA. Identification of blood vascular endothelial stem cells by the expression of protein C receptor. *Cell Res* (2016) 26(10):1079–98. doi:10.1038/cr.2016.85

35. MacEwan DJ, TFN ligands and receptors – a matter of life and death. *Br J Pharmacol* (2002) 135(4):855–75. doi:10.1038/sj.bjp.0704549

36. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. *Sci Signal* (2014) 7(344):re8. doi:10.1126/scisignal.2005189

37. Cho et al. EndMT in Inflammation-Induced Endothelial Dysfunction

38. Yu QC, Song W, Wang D, Zeng YA. Identification of blood vascular endothelial stem cells by the expression of protein C receptor. *Cell Res* (2016) 26(10):1079–98. doi:10.1038/cr.2016.85
endothelial cell. Exp Mol Pathol (2017) 102(3):377–83. doi:10.1016/j. ymep.2017.03.007

57. Zuo X, Zhuo Q, Wang X, Chen Z, Peng K, Lu X, et al. Serum response factor induces endothelial-mesenchymal transition in glomerular endothelial cells to aggregate proteinuria in diabetic nephropathy. Physiol Genomics (2016) 48(10):711–8. doi:10.1152/physiolgenomics.00082.2016

58. Ma Z, Zha L, Liu Y, Wang Z, Yang Y, Chen L, et al. Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-beta1 signaling. Front Pharmacol (2017) 8:473. doi:10.3389/fphar.2017.00473

59. Peng H, Li Y, Wang C, Zhang J, Chen Y, Chen W, et al. ROCK1 induces endothelial-to-mesenchymal transition in glomeruli to aggregate albuminuria in diabetic nephropathy. Sci Rep (2016) 6:20304. doi:10.1038/srep20304

60. Shang J, Zhang Y, Jiang Y, Li Z, Duan Y, Wang L, et al. NOD2 promotes endothelial-to-mesenchymal transition of glomerular endothelial cells via MEK/ERK signaling pathway in diabetic nephropathy. Biochem Biophys Res Commun (2017) 484(2):435–41. doi:10.1016/j.bbrc.2017.01.155

61. Tang RN, Lv LL, Zhang JD, Dai HY, Li Q, Zheng M, et al. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int J Cardiol (2013) 162(2):92–9. doi:10.1016/j.ijcard.2011.06.052

62. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Viemann D, Goebeler M, Schmid S, Nordhues U, Klimmek K, Sorg C, Murakami S, Morioka T, Nakagawa Y, Suzuki Y, Arakawa M, Oite T. Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms. Circ Res (2007) 100(2):158–73. doi:10.1161/01.RES.0000255691.76142.4a

63. Kim M, Choi SH, Jin YB, Lee HJ, Yi YH, Kim J, et al. The effect of oxidized low-density lipoprotein (ox-LDL) on radiation-induced endothelial-to-mesenchymal transition. Int J Radiat Biol (2013) 89(5):356–63. doi:10.3109/10723575.2013.763193

64. Spillmann F, Miteva K, Pieske B, Tschope C, Van Linthout S. High-density lipoprotein (HDL) demonstrates site-specific endothelial activation in mouse models of sepsis. Mol Vis (2008) 14(205):2623–31. doi:10.1084/jem.20080398

65. Shaffer II, Invernici G, Ponti D, Corsini E, Cristini S, Frigerio S, Colombo A, et al. Fibulin-1 suppresses endothelial to mesenchymal transition in the cardiovascular system. Am J Pathol (2016) 184:95–102. doi:10.1016/j.ajpath.2017.07.014

66. Smythies J, Wynna TA. Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 214(2):199–210. doi:10.1002/path.2277

67. Yoshimatsu Y, Watabe T. Roles of TGF-beta signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflamm (2011) 2011:724080. doi:10.4061/2011/724080

68. Zhou X, Chen C, Cai J, Chen LZ, Gao YS, Wang LX, et al. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway. Drug Des Devel Ther (2015) 9:5499–611. doi:10.2147/DDDT.S85399

69. Zhang Y, Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA, Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA. Human pulmonary vascular progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ Res (2006) 99(8):861–9. doi:10.1161/01.RES.0000245188.41002.2c

70. Zhang Y, Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA. Human pulmonary vascular progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ Res (2006) 99(8):861–9. doi:10.1161/01.RES.0000245188.41002.2c

71. Cheng X, Cai J, Zhou X, Chen L, Gao Y, Gao Z, et al. Protective effect of spironolactone on endothelial-to-mesenchymal transition in HUV-ECs via Notch pathway. Cell Physiol Biochem (2015) 36(1):191–200. doi:10.1158/0002-9440(10)62243-2

72. Gao H, Zhang J, Liu T, Shi W. Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study. Mol Vis (2011) 17:3406–14.
94. Correia AC, Moonen JR, Brinker MG, Krenning G. FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-beta signaling. J Cell Sci (2016) 129(3):569–79. doi:10.1242/jcs.176248

95. Chen PY, Qin LF, Tellides G, Simons M. Fibroblast growth factor receptor 1 is a key inhibitor of TGF beta signaling in the endothelium. Sci Signal (2014) 7(344):ra90. doi:10.1126/scisignal.2005504

96. Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, et al. Linagliptin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition. Diabetes (2014) 63(6):2120–31. doi:10.2337/dc14-0309

97. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation (2007) 116(24):2782–5. doi:10.1161/CIRCULATIONAHA.107.749655

98. Bostrom KI, Yao J, Guirland P, Blazquez-Medela AM, Yao Y. Endothelial-mesenchymal transition in atherosclerosis and calcification. Atherosclerosis (2016) 253:124–7. doi:10.1016/j.atherosclerosis.2016.08.046

99. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun (2016) 7:11853. doi:10.1038/ncomms11853

100. Zhou H, Chen X, Chen L, Zhou X, Zheng G, Zhang H, et al. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension (2012) 59(5):958–65. doi:10.1161/HYPERTENSIONAHA.111.183905

101. Wu M, Tang RN, Liu H, Pan MM, Lv LL, Zhang JD, et al. Cinaracelt ameliorates cardiac dysfunction in uremic hearts through suppression of endothelial-to-mesenchymal transition. Int J Cardiol (2014) 171(3):e65–9. doi:10.1016/j.ijcard.2013.11.105

102. Wylie-Sears J, Levine RA, Bischoff J. Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-beta-induced phosphorylation of ERK. Biochem Biophys Res Commun (2014) 446(4):870–5. doi:10.1016/j.bbrc.2014.03.014

103. Zhou H, Chen X, Chen L, Zhou X, Zheng G, Zhang H, et al. Anti-fibrosis effect of scutellarin via inhibition of endothelial-mesenchymal transition on isoprenaline-induced myocardial fibrosis in rats. Molecules (2014) 19(10):15611–23. doi:10.3390/molecules191015611

104. Bischoff J, Casanovas G, Wylie-Sears J, Kim DH, Bartlo PE, Guerrero JL, et al. CD45 Expression in Mitral valve endothelial cells after myocardial infarction. Circ Res (2016) 119(11):1215–25. doi:10.1161/CIRCRESAHA.116.309598

105. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis and endothelial-mesenchymal transition. Atherosclerosis (2016) 253:124–7. doi:10.1016/j.atherosclerosis.2016.08.046

106. Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzereoni F, Iliakoulis V, et al. The Endothelial-mesenchymal transition in systemic sclerosis is induced by Endothelin-1 and transforming growth factor-beta and may be blocked by macitentan, a dual endothelin-1 receptor antagonist. J Rheumatol (2015) 42(10):1808–16. doi:10.3899/jrheum.150088

107. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber LC. Inflammatory cytokines in pulmonary hypertension. Respir Res (2014) 15:47. doi:10.1186/1465-9921-15-47

108. Cho Y, Yuan T, Zhang H, Yan Y, Wang D, Fang L, et al. Activation of Nrf2 attenuates pulmonary vascular remodeling via inhibiting endothelial-to-mesenchymal transition: an insight from a plant polyphenol. Int J Biol Sci (2017) 13(8):1067–81. doi:10.7150/ijbs.20316

109. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMP2 attenuates pulmonary hypertension. Eur Respir J (2012) 39(2):329–43. doi:10.1183/09031936.00187310

110. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMP2 attenuates pulmonary hypertension. Eur Respir J (2012) 39(2):329–43. doi:10.1183/09031936.00187310

111. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun (2016) 7:11853. doi:10.1038/ncomms11853

112. Malhotra R, Burke MF, Martyn T, Shaktarzi HR, Thayer TE, O’Rourke C, et al. Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency. PLoS One (2015) 10(1):e0117098. doi:10.1371/journal.pone.0117098

113. Cavaleri M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res (2014) 164(4):323–35. doi:10.1016/j.trsl.2014.05.001

114. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest (2011) 121(6):2111–7. doi:10.1172/JCI57132

115. Cavaleri M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res (2014) 164(4):323–35. doi:10.1016/j.trsl.2014.05.001

116. Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzereoni F, Iliakoulis V, et al. The Endothelial-mesenchymal transition in systemic sclerosis is induced by Endothelin-1 and transforming growth factor-beta and may be blocked by macitentan, a dual endothelin-1 receptor antagonist. J Rheumatol (2015) 42(10):1808–16. doi:10.3899/jrheum.150088

117. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber LC. Inflammatory cytokines in pulmonary hypertension. Respir Res (2014) 15:47. doi:10.1186/1465-9921-15-47

118. Cho Y, Yuan T, Zhang H, Yan Y, Wang D, Fang L, et al. Activation of Nrf2 attenuates pulmonary vascular remodeling via inhibiting endothelial-to-mesenchymal transition: an insight from a plant polyphenol. Int J Biol Sci (2017) 13(8):1067–81. doi:10.7150/ijbs.20316

119. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMP2 attenuates pulmonary hypertension. Eur Respir J (2012) 39(2):329–43. doi:10.1183/09031936.00187310

120. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation (2007) 116(24):2782–5. doi:10.1161/CIRCULATIONAHA.107.749655

Conflict of Interest Statement: The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.